Table 1 Baseline patient characteristics of each included article
References | Group | No. | Sex (M/ F) | Median age (years, range) | HCT-CI | ECOG-PS/ KPS* | Diseases | Donor source | Median CD 34 + (× 106 cells/kg, range) | Study period | Type | Quality assessment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Morabito 2002 [23] | OP | 29 | 19/10 | 55.3 | NR | NR | MM: 29 | PBSC | 5.3 | 1998–2001 | R | Selection: 3 Comparability: 2 Outcome: 2 |
IP | 27 | 18/9 | 49.6 | NR | NR | MM: 27 | PBSC | 6.4 | ||||
Ferna’ndez-Avilés 2006 [24] | OP | 50 | 31/19 | 47 (20–65) | NR | 0: 25, 1: 18, 2: 7 | MM:13, Lym: 28, ALL: 4, AML: 1, CML: 2, CLL: 2 | PBSC except 1 case was mixed source | 3.2 (1.8–21) | 2000–2005 | R | Selection: 3 Comparability: 2 Outcome: 2 |
IP | 50 | 27/23 | 50 (20–68) | NR | 0: 23, 1: 18, 2: 9 | MM:13, Lym:28, ALL 3, AML: 2, CML: 2, CLL: 2 | PBSC except 1 case was mixed source | 2.7 (0.9–15) | ||||
Martino 2015 [25] | OP | 25 | 18/7 | 59 (42–65) | NR | NR | MM: 25 | NR | 5 (2.1–5.9) | NR | P | Selection: 4 Comparability: 2 Outcome: 2 |
IP | 33 | 20/13 | 62 (43–67) | NR | NR | MM 33 | NR | 4.9 (2.1–5.8) | ||||
Graff 2015 [26] | OP | 95 | 63/32 | 58 (20–76) | 0–2: 57 ≥3: 38 | ≤80: 6, 90: 49, 100: 40 | MM: 63, Lym: 32 | NR | 4.4 (1.9–12.9) | 2009–2012 | R | Selection: 3 Comparability: 2 Outcome: 3 |
IP | 135 | 86/49 | 59 (21–76) | 0–2: 64 ≥3: 71 | ≤80: 36, 90: 72, 100: 27 | MM: 88, Lym: 47 | NR | 4.6 (1.9–16.5) | ||||
Paul 2015 [27] | OP | 82 | 51/31 | 59 (28–71) | 0–1: 82 | NR | MM: 82 | NR | NR | 2003–2010 | R | Selection: 3 Comparability: 2 Outcome: 2 |
IP | 219 | 128/91 | 60 (29–75) | 0–1: 219 | NR | MM: 219 | NR | NR | ||||
Reid 2016 [28] | OP | 58 | 38/20 | 58 (17–72) | 0–2: 46 ≥3: 12 | NR | Lym: 58 | PBSC | 4.6 (2–16.8) | 2011–2014 | R | Selection: 4 Comparability: 2 Outcome: 2 |
IP | 49 | 30/19 | 59 (16–74) | 0–2: 37 ≥ 3: 12 | NR | Lym: 49 | PBSC | 4.2 (2–18.9) | ||||
Abid 2017 [29] | OP | 10 | 6/4 | 56 (39–62) | 0–2: 10 | 0: 6, 1: 4, 2: 0 | MM: 10 | PBSC | 9.2 (2.8–18.9) | 2011–2015 | R | Selection: 2 Comparability: 2 Outcome: 2 |
IP | 11 | 6/5 | 58 (45–64) | 0–2: 9, ≥3: 2 | 0: 5, 1: 4, 2: 2 | MM: 11 | PBSC | 8.5 (2.5–17.8) | ||||
Lisenko 2017 [30] | OP | 14 | 9/5 | NR | NR | 0–1: 14 | MM: 14 | PBSC | 9.7 (7.4–24.8) | 2012–2016 | R | Selection: 3 Comparability: 2 Outcome: 2 |
IP | 7 | 6/1 | NR | NR | 0–1: 7 | MM: 7 | PBSC | 13.7 (9.1–23) | ||||
Shah 2017 [31] | OP | 377 | 234/143 | 58 (34–78) | < 3: 207 ≥ 3: 170 | 90* | MM: 377 | NR | NR | 2008–2012 | R | Selection: 3 Comparability: 2 Outcome: 2 |
IP | 669 | 369/300 | 62 (31–82) | < 3: 301 ≥ 3: 368 | 90* | MM: 669 | NR | NR |